The Pan-Canadian Oncology Drug Review (pCODR) will be considering an application for the drug Everolimus (Afinitor) indicated for Gastrointestinal and Lung Neuroendocrine (NET) Tumours. Everolimus is a cancer medicine that [...]
We are pleased to announce that this week, we are officially launching our 177Lu-octreotate PRRT clinical trial at CHU de Québec, which is called: Personalized Peptide Receptor Radionuclide Therapy of [...]
CNETS Canada's President, Jackie Herman is quoted in Maclean’s Magazine Digestive Health Supplement
This past March CNETS Canada held its first Scientific and Medical Advisory Board (SMAB) meeting in Toronto. The SMAB is composed of prominent Canadian physicians and scientists passionate about the [...]
Neuroendocrine Tumour (NET) Incidence Significantly Increases in Canada An original article published in Cancer, February 15, 2015, by the American Cancer Society showed that the incidence of Neuroendocrine Tumours has [...]